Clay Siegall is the co-founder and CEO of Seattle Genetics. Siegall founded Seattle Genetics in 1998. Siegall’s medical focus is on targeted cancer therapies. Doctor Clay Siegall has led Seattle Genetics‘ fundraising activities bringing in more than $330 million through private and public financing.
Siegall sits on the Editorial Board of three scientific journals and also sits on the Board of Scientific Counselors for the Cancer Treatment Research Foundation. Dr. Siegall earned a Ph.D in Genetics from George Washington University and B.S. in Zoology from University of Maryland. Dr. Clay Siegall has authored more than 70 publications within his industry.
Siegall’s Seattle Genetics was founded in 1997 and is based in Washington. Seattle Genetics is the leader in antibody-drug conjugates, technology that delivers cell-killing agents directly to cancer cells. Seattle Genetics is launching a clinical development program evaluating several health issues including Hodgkin lymphoma.
As of March 2001, Seattle Genetics has been trade publicly on the NASDAQ Stock Market. Clay Siegall has entered into multiple worldwide collaboration and several national collaborations with companies including Genentech, MedImmune and Bayer. The collaborations have generated more than $65 million for Seattle Genetics.
Clay Siegall is planning to introduce 12 new drugs and is planning on hiring 100 more employees. Siegall has made several appearances on cable television including on CNBC discussing medication costs on a drug he was working on.
Dr. Clay Siegall has been a revolutionary expert in the medical field, drawing praise from his colleagues and other medical leaders from across the country. Clay Siegall continues to build up Seattle Genetics as much as it can and revolutionize cancer treatments and possibly discover a cure for cancer.